| pubmed-article:7675822 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0013030 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0028351 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0003693 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0033551 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C0574032 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:7675822 | lifeskim:mentions | umls-concept:C2348480 | lld:lifeskim |
| pubmed-article:7675822 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:7675822 | pubmed:dateCreated | 1995-10-19 | lld:pubmed |
| pubmed-article:7675822 | pubmed:abstractText | We have previously demonstrated that adrenaline infusion increases the thromboxane/leukotriene (TX/LT) ratio in whole blood in healthy volunteers. The aim of the present study was to see whether other catecholamines--noradrenaline and dopamine--are also capable of modulating arachidonic acid (AA) metabolism in man. Low doses of noradrenaline (0.025 microgram/kg/min) and dopamine (3.0 micrograms/kg/min), which did not change hemodynamics, were infused for 60 min into healthy male volunteers. Both dopamine and noradrenaline decreased TX synthesis stimulated by spontaneous clotting, but no remarkable effect was seen when calcium ionophore A23187 was used as a stimulus. Dopamine but not noradrenaline increased prostaglandin E2 (PGE2) synthesis in A23187-stimulated whole blood. They both marginally decreased LTB4 formation in A23187-stimulated whole blood. The findings indicate that not only adrenaline but also noradrenaline and dopamine modulate AA metabolism in man. | lld:pubmed |
| pubmed-article:7675822 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7675822 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7675822 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7675822 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:7675822 | pubmed:issn | 0952-3278 | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:VapaataloHH | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:Metsä-KeteläT... | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:KaukinenSS | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:SeppäläEE | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:AlankoJJ | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:RiuttaAA | lld:pubmed |
| pubmed-article:7675822 | pubmed:author | pubmed-author:KerttulaTT | lld:pubmed |
| pubmed-article:7675822 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7675822 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:7675822 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7675822 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7675822 | pubmed:pagination | 47-52 | lld:pubmed |
| pubmed-article:7675822 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:meshHeading | pubmed-meshheading:7675822-... | lld:pubmed |
| pubmed-article:7675822 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7675822 | pubmed:articleTitle | Noradrenaline and dopamine infusions modulate arachidonic acid cyclooxygenase and 5-lipoxygenase pathways ex vivo in man. | lld:pubmed |
| pubmed-article:7675822 | pubmed:affiliation | Department of Clinical Chemistry, Tampere University Hospital, Finland. | lld:pubmed |
| pubmed-article:7675822 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7675822 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:7675822 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:7675822 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:7675822 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
